Recruiting

Testing a new form of an MS medication given under the skin

Plain-English translation of NCT07609719 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Read our Multiple Sclerosis research guide →

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This trial is testing ocrelizumab given as a shot under the skin instead of through an IV infusion. You would be eligible if you are currently taking another similar MS medication and are switching to this treatment. Researchers want to measure how well the medication works, how safe it is, and whether people are satisfied with this easier way of receiving it.

Many people with MS currently receive their medication through IV infusions at a hospital or clinic, which requires more time and travel. This trial is exploring whether giving the treatment as a simple injection at home could work just as well and be more convenient for patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsing or primary progressive multiple sclerosis
you have been taking another approved anti-CD20 MS medication (such as ofatumumab, ublituximab, or ocrelizumab given by IV)
you are stopping your current MS medication because you prefer to, have insurance coverage issues, or have logistical reasons like moving
your disability score is between 0 and 6.5 on the standard MS disability scale
you are able to undergo MRI scans without trouble

You likely don't qualify if…

you stopped your current MS medication because you had a serious allergic reaction or severe infection that your doctor believed was caused by the treatment
you have an active infection, HIV, hepatitis, or a history of a rare brain infection called PML
you have received a bone marrow or stem cell transplant in the past
you are allergic to ocrelizumab or any ingredients in this medication
you have taken certain other strong immunosuppressant medications like cladribine, alemtuzumab, or mitoxantrone

What participation looks like

You would receive two injections of the medication under your skin — one at the beginning of the study and another at 24 weeks. You would visit the study clinic for evaluations, blood work, and MRI brain scans to measure how well the medication is working and how your MS is progressing. The study will also ask you about your satisfaction with this new way of receiving treatment and monitor you for any side effects.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Testing a new form of an MS medication given under the skin

What is this trial?

Do you qualify?

What participation looks like

Trial locations(11 sites)